Answers are grounded in this paper and cite their sources.
The study demonstrates the correlation between pain intensity and radiological stage in patients with medication-related osteonecrosis of the jaw, suggesting diagnostic implications.
Introduction: Osteonecrosis of the jaw is defined as avascular necrosis of the alveolar cancellous and cortical bone of the maxilla or mandible, most commonly as the result of a therapeutic intervention-either radiotherapy or pharmacological treatment. Certain criteria define medication-related osteonecrosis of the jaw (MRONJ) and can be staged in four degrees. MRONJ develops as a consequence of the systemic effects of certain medications, primarily bisphosphonates, that inhibit bone remodeling by suppressing the activity of bone-resorbing cells-osteoclasts. Aim. The study aimed to compare the multislice computed tomography (MSCT) radiological changes in MRONJ caused by bisphosphonates stage to clinical signs and symptoms, such as the presence of pain, infection and fistula in patients with diagnosed MORNJ. Materials and Methods: Patient data were collected from medical records and included duration of bisphosphonate therapy, stage of MRONJ, MSCT radiograph findings, and questionnaire about the presence and intensity of pain, measured using a numerical pain rating scale. Results: All patients had been receiving oral antiresorptive bisphosphonate therapy for periods ranging from 1 to 15 years; 63.63% had been on bisphosphonate therapy for more than three years, 27.27% for less than three years, and 9.09% for more than 15 years. In patients who developed Stage II, the mean pain intensity was 5.1 ± 1.1; Stage III reported pain level 8, Stage II MRONJ experienced mild pain 2. There was no drug holiday in any patient involved in the study. Conclusion: Radiologists play an important role in the early diagnosis of all stages of MRONJ. Pain could be considered as an early sign of this pathological condition of the bone, and it correlates with the stage of MRONJ in lesions caused by bisphosphonate intake.
No takes yet. Share an insight, caveat, or question.
Maja Jocić (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: